Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

[1] Morales-Vásquez F(2016)High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma J Ovarian Res 9 41-257

[2] Pedernera E(2015)Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial Lancet 386 249-953

[3] Reynaga-Obregón J(2010)Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 943-480

[4] López-Basave HN(2015)Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation Health Technol Assess 19 1-1534

[5] Gómora MJ(2009)Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer Int J Gynecol Cancer 19 1529-153

[6] Carlón E(1999)Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer Gynecol Oncol 72 148-1184

[7] Cárdenas S(2003)Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer Br J Cancer 89 1180-1582

[8] Kehoe S(2013)A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer Int J Gynecol Cancer 23 1577-73

[9] Hook J(2011)Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer Cancer Chemother Pharmacol 67 69-512

[10] Nankivell M(2004)Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study Gynecol Oncol 95 506-2612

[1] Morales-Vásquez F(2016)High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma J Ovarian Res 9 41-257

[2] Pedernera E(2015)Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial Lancet 386 249-953

[3] Reynaga-Obregón J(2010)Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 943-480

[4] López-Basave HN(2015)Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation Health Technol Assess 19 1-1534

[5] Gómora MJ(2009)Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer Int J Gynecol Cancer 19 1529-153

[6] Carlón E(1999)Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer Gynecol Oncol 72 148-1184

[7] Cárdenas S(2003)Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer Br J Cancer 89 1180-1582

[8] Kehoe S(2013)A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer Int J Gynecol Cancer 23 1577-73

[9] Hook J(2011)Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer Cancer Chemother Pharmacol 67 69-512

[10] Nankivell M(2004)Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study Gynecol Oncol 95 506-2612